Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study will look at how medications affect the pattern of blood flow in the brain. This study will use a special type of MRI (magnetic resonance imaging) scan called perfusion MRI to make measurements of cerebral (brain) blood flow. The medications we will use in this study are scopolamine (commonly used to treat motion sickness), mecamylamine (used to treat high blood pressure), and donepezil (used to treat memory loss). Cognitive testing will also be obtained, and correlated with the blood flow patterns in the brain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

NCT00001917

Alzheimer's Disease Healthy

COMPLETED

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

NCT00637442

Alzheimer's Disease

UNKNOWN NA

BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

NCT00887601

Dementia

COMPLETED PHASE1

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

NCT04510168

Alzheimer Disease Dementia

COMPLETED

Magnetic Resonance Imaging Studies of Motor and Thought Processes

NCT00001361

Cerebrovascular Disorder Healthy Movement Disorder +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Project Summary: This research project will investigate the value of combined pharmacologic manipulation and arterial spin-labeled perfusion MRI (pharmacologic ASL-pMRI) as an in vivo probe of cholinergic function. Methods to investigate cholinergic function in vivo are needed to better understand the role of acetylcholine in the physiology of the cerebral cortex, and in cognitive processes in health and in disease states. In this study, pharmacologic ASL-pMRI will be used to characterize the normal cerebral perfusion response to cholinergic manipulation in young healthy subjects. Cognitive measures will also be obtained and correlated with cerebral perfusion changes. Pharmacologic ASL-pMRI and cognitive testing will then be used to study how the cholinergic response is altered with normal aging and in delirium

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholinergic Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young

Young healthy controls, aged 21-35

Group Type EXPERIMENTAL

Scopolamine

Intervention Type DRUG

Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)

Placebo

Intervention Type DRUG

IM or PO placebo

Older

Older healthy controls, aged 65-80

Group Type EXPERIMENTAL

Scopolamine

Intervention Type DRUG

Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)

Placebo

Intervention Type DRUG

IM or PO placebo

Donepezil

Intervention Type DRUG

donepezil 5mg PO x 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Scopolamine

Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)

Intervention Type DRUG

Placebo

IM or PO placebo

Intervention Type DRUG

Donepezil

donepezil 5mg PO x 1

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aricept

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy volunteers

Exclusion Criteria

* Any neurological condition, such as brain tumor, history of stroke, seizure disorder, attention deficit disorder, normal pressure hydrocephalus, dementia, traumatic brain injury
* Any major medical conditions, such a cancer, diabetes, glaucoma, prostate disease, uncontrolled hypertension
* antihistamine use
* tricyclic antidepressant use
* presence of metal in body, including pacemaker, defibrillator, neurostimulator, metal implants, or foreign metal objects such as bullets or shrapnel.
* anxiety or panic disorder
* history of claustrophobia
* pregnancy

Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes